Over 10 years we help companies reach their financial and branding goals. Engitech is a values-driven technology agency dedicated.



411 University St, Seattle, USA

+1 -800-456-478-23


Next-Gen Delivery 

Myeloid is powered by our team of talented, driven scientists and biotech industry experts whose expertise spans oncology, immunology, mRNA biology, cell therapy, synthetic biology, and gene delivery. 

Gene delivery and writing using mRNA 

Harnessing the frequent migration of myeloid cells from the blood into solid tumors as well as sites of inflammation 

Stable mRNA expression 

Directing phagocytic properties of myeloid cells, including the capability to recognize and engulf cancer cells 

Prime medicine collaboration 

Empowering myeloid cells to produce anti-tumor agents and modify the tumor microenvironment 

Field rights retained 

Bridging innate and adaptive immunity, to elicit a broad anti-tumor immune response with tumor-specific T cells 


Lorem Ipsum 1

Our proprietary RNA-based, retrotransposon mediated gene-insertion technology, (RetroT™), has applications across gene editing and delivery.  Retrotransposons are genetic elements that have the capability of replicating through reverse transcription of an RNA transposition intermediate. They contribute to structural changes and more importantly to gene regulation.


Lorem Ipsum 2

Our retrotransposon-based approach relies on mRNA to deliver genetic sequences and integration enzymes in a single mRNA strand. This breakthrough technology offers the potential to deliver gene-sized pieces of DNA into the genome, which are larger than currently possible with existing gene editing technologies. As a result, it holds the potential to significantly expand the type and scope of genetic errors that can be reversed in situ.


Lorem Ipsum 3

In March 2022, we announced that we entered into an exclusive research collaboration and option agreement with Prime Medicine to develop and accelerate RetroT.  As part of the deal, Myeloid received a $45M upfront payment and the company is eligible for significant future milestones.